WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013126726) DOUBLE TRANSGENIC T CELLS COMPRISING A CAR AND A TCR AND THEIR METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Considered void 2013-12-23 00:00:00.0


Pub. No.:    WO/2013/126726    International Application No.:    PCT/US2013/027357
Publication Date: 29.08.2013 International Filing Date: 22.02.2013
IPC:
C07K 14/705 (2006.01)
Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; Center for Technology Transfer 3160 Chestnut Street Suite 200 Philadelphia, PA 19104-6283 (US)
Inventors: JUNE, Carl H.; (US).
KAWALEKAR, Omkar U.; (US).
ZHAO, Yangbing; (US).
SCHOLLER, John; (US)
Agent: DOYLE, Kathryn; Saul Ewing, LLP Centre Square West 1500 Market Street, 38th Floor Philadelphia, PA 19102 (US)
Priority Data:
61/601,905 22.02.2012 US
Title (EN) DOUBLE TRANSGENIC T CELLS COMPRISING A CAR AND A TCR AND THEIR METHODS OF USE
(FR) LYMPHOCYTES T DOUBLES TRANSGÉNIQUES COMPORTANT UN CAR ET UN TCR, ET LEURS PROCÉDÉS D'UTILISATION
Abstract: front page image
(EN)The invention provides compositions and methods for reducing and preventing tumor escape from immunotherapy. Specifically, the invention relates to administering a genetically modified T cell comprising both a TCR and a CAR. The invention provides an isolated nucleic acid encoding a T cell receptor (TCR) and a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence comprises a TCR-a sequence, a TCR-β sequence, a CAR antigen binding domain and a costimulatory signaling domain sequence. In one embodiment, the CAR sequence further comprises the nucleic acid sequence of a CD3 zeta signaling domain.
(FR)L'invention concerne des compositions et des procédés qui permettent de réduire et de prévenir l'échappement tumoral à l'immunothérapie. En particulier, l'invention consiste à administrer un lymphocyte T génétiquement modifié comportant à la fois un TCR et un CAR. L'invention met en oeuvre un acide nucléique isolé codant un récepteur des lymphocytes T (TCR) et un récepteur de l'antigène chimère (CAR), la séquence d'acide nucléique isolée comprenant une séquence TCR-a, une séquence TCR-β, un domaine de liaison à l'antigène CAR et une séquence de domaine de signalisation à costimulation. Selon un mode de mise oeuvre, la séquence CAR comprend également la séquence d'acide nucléique d'un domaine de signalisation zêta CD3.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)